Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    22663011 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Condition: Melanoma
Interventions: Drug: GSK1120212;   Drug: Chemotherapy
2 Not yet recruiting Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib

Indicates status has not been verified in more than two years